cs.AIApr 23, 2026

BioMiner: A Multi-modal System for Automated Mining of Protein-Ligand Bioactivity Data from Literature

Authors: Jiaxian Yan, Jintao Zhu, Yuhang Yang, Qi Liu, Kai Zhang, Zaixi Zhang, Xukai Liu, Boyan Zhang, +3 more

Organizations: State Key Laboratory of Cognitive Intelligence, University of Science and Technology of China · Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University · Princeton University · Huazhong University of Science and Technology · Infinite Intelligence Pharma

Abstract

Protein-ligand bioactivity data published in the literature are essential for drug discovery, yet manual curation struggles to keep pace with rapidly growing literature. Automated bioactivity extraction remains challenging because it requires not only interpreting biochemical semantics distributed across text, tables, and figures, but also reconstructing chemically exact ligand structures (e.g., Markush structures). To address this bottleneck, we introduce BioMiner, a multi-modal extraction framework that explicitly separates bioactivity semantic interpretation from ligand structure construction. Within BioMiner, bioactivity semantics are inferred through direct reasoning, while chemical structures are resolved via a chemical-structure-grounded visual semantic reasoning paradigm, in which multi-modal large language models operate on chemically grounded visual representations to infer inter-structure relationships, and exact molecular construction is delegated to domain chemistry tools. For rigorous evaluation and method development, we further establish BioVista, a comprehensive benchmark comprising 16,457 bioactivity entries curated from 500 publications. BioMiner validates its extraction ability and provides a quantitative baseline, achieving an F1 score of 0.32 for bioactivity triplets. BioMiner's practical utility is demonstrated via three applications: (1) extracting 82,262 data from 11,683 papers to build a pre-training database that improves downstream models performance by 3.9%; (2) enabling a human-in-the-loop workflow that doubles the number of high-quality NLRP3 bioactivity data, helping 38.6% improvement over 28 QSAR models and identification of 16 hit candidates with novel scaffolds; and (3) accelerating protein-ligand complex bioactivity annotation, achieving a 5.59-fold speed increase and 5.75% accuracy improvement over manual workflows in PoseBusters dataset.

Explore similar work

CardsList
May 11, 2026q-bio.QM

Beyond Manual Curation: Augmenting Targeted Protein Degradation Databases via Agentic Literature Extraction Workflows

Predictive models in biomedicine depend on structured assay data locked in the text, tables, and supplements of primary publications. This bottleneck is especially acute in targeted protein degradation (TPD), where each assay record must combine compound identity, degradation target, recruiter, assay context, and endpoint values reported across sections, tables, and supplementary files. Inconsistent compound identifiers and incomplete or implicit assay context further demand domain-specific logic that generic LLM pipelines do not provide. Existing molecular glue and PROTAC databases are manually curated and often lack the experimental context required for downstream modeling. We formulate TPD database extraction as a domain-specific curation task and present an expert-in-the-loop LLM workflow, evaluated through a triangular comparison among LLM predictions, standardized baseline records, and expert-annotated ground truth. A lightweight cross-validated prompt-refinement module adapts extraction instructions from scarce expert annotations. With only seven annotated molecular glue publications, the workflow achieved record-level F1=0.98F_1 = 0.98 and transferred to PROTACs by terminology substitution alone, maintaining record-level F1>0.93F_1 > 0.93. Applied at scale, it expanded molecular glue and PROTAC databases by 81% and 92% records, respectively, with 92% and 82.5% of newly recovered records validated as correct upon expert review. The workflow also recovered kinetic and assay-context information essential for cross-study potency comparison and condition-aware degradation modeling. We release the workflow, prompts, evaluation code, and extracted datasets as resources for TPD data curation and AI-assisted scientific curation more broadly.
Yaochen Rao, Farzaneh Jalalypour, N. M. Anoop Krishnan +1
ProteinData-CurationBiomedicalExtractionDegradationLarge Language Model Pipelines
AskPDF
Apr 17, 2026cs.LG

An Interpretable Framework Applying Protein Words to Predict Protein-Small Molecule Complementary Pairing Rules

Despite the high accuracy of 'black box' deep learning models, drug discovery still relies on protein-ligand interaction principles and heuristics. To improve interpretability of protein-small molecule binding predictions, we developed the PWRules framework, which applies binding affinity data to identify privileged small molecule fragments and subsequently defines complementary pairing rules between these fragments and protein words (semantic sequence units) through an interpretability module. The resulting word-fragment rules are then ranked by the PWScore function to prioritize active compounds. Evaluations on benchmark datasets show that PWScore achieves competitive performance comparable to the physics-based model (Glide) and the deep learning model (PSICHIC) and shows broad applicability for protein targets outside the training dataset, e.g., SARS-CoV-2 main protease. Notably, PWScore captures complementary interaction information, yielding superior enrichment performance when integrated with these established methods. Structural analysis of protein-ligand complexes indicates that learned word-fragment rules are significantly enriched near ligand-binding pockets, despite training without explicit structural guidance. By extracting and applying complementary pairing rules, PWRules provides an interpretable framework for drug discovery.
Jingke Chen, Jingrui Zhong, Tazneen Hossain Tani +3
Drug DesignModel Interpretability MethodsLexical Stability
AskPDF
Jul 4, 2025cs.LG

Structure-Aware Compound-Protein Affinity Prediction via Graph Neural Networks with Group Lasso Regularization

Explainable artificial intelligence approaches accelerate drug discovery by improving molecular representation learning, identifying key molecular structures, and rationalizing drug property prediction. However, developing end-to-end explainable models for target-specific structure-activity relationship modeling remains challenging because compound-protein interaction data are often limited for individual targets, and small changes in chemical substituents or local structural motifs can cause large differences in molecular properties. Therefore, effectively leveraging structural and property information to identify key moieties associated with compound-protein affinity is essential. We propose a graph neural network (GNN) framework that uses property and structural information from activity-cliff molecule pairs targeting specific proteins to predict compound-protein affinity, measured by half-maximal inhibitory concentration (IC50), and explain property differences. To improve explainability, we trained GNNs with structure-aware loss functions using group lasso and sparse group lasso regularization, which prune and highlight molecular subgraphs relevant to activity differences. We applied this framework to activity-cliff data from molecules targeting six tyrosine-protein kinases across the Src, Abl, and Tec families, as well as anaplastic lymphoma kinase. Integrating common- and uncommon-node information with sparse group lasso improved target-specific molecular property prediction, producing lower root mean square errors and higher Pearson correlation coefficients. Regularization also enhanced GNN feature attribution by improving graph-level global direction scores and atom-level coloring accuracy. These results support more interpretable drug discovery pipelines, particularly for identifying critical molecular substructures during lead optimization.
Zanyu Shi, Yang Wang, Pathum M. Weerawarna +4
Drug DesignDrug DiscoveryProteinGraph Neural NetworksLasso
AskPDF